Physician profile
Glenn Goldstein
NPI 1811901044
$7,169.11
in general payments reported to CMS, 2019-2025
12 companies · $625 in 2025
The $625 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,098 · 2020: $287 · 2021: $791 · 2022: $1,351 · 2023: $808 · 2024: $1,210 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,642.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,876.61 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Genesys Orthopedics Systems, L.L.C. | $780.13 | 2022 | |
| Horizon Therapeutics Plc | $487.36 | 2019-2021 | |
| Spinal Simplicity, LLC | $352.88 | 2024-2025 | Ha Minuteman G3-R |
| Spr Therapeutics, INC | $246.17 | 2023-2025 | Sprint Pns System |
| Abbott Laboratories | $107.76 | 2022 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Relievant Medsystems, INC. | $96.43 | 2023 | Intracept |
| Pacira Therapeutics, INC. | $37.38 | 2021 | |
| Nevro Corp. | $36.75 | 2020 | |
| Bioventus LLC | $34.24 | 2021 | |
| Vertiflex, INC. | $15.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.